News

PHALCON-EE is a randomized, double-blind, two-phase, multicenter Phase 3 trial that is planned to enroll approximately 1,000 patients with EE in the U.S. and Europe. The first phase

Under the deal, Astellas US Holding wholly-owned subsidiary Asilomar Acquisition will acquire Audentes by paying $60 per share in cash. Audentes chairman and CEO Matthew Patterson said: “With

The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the treatment of patients having Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle

The funding will be used to develop an innovative anticoagulant treatment with minimal bleeding risk, to better meet patient need. The 18-month preclinical drug discovery project brings together

SENS-111 is an orally available small molecule histamine type 4 receptor antagonist, which delivers an inhibitory effect on vestibular neuron activity. According to the company, the SENS-111 was

Imfinzi holds approvals for the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy across 54 countries, including the US, the European Union,

It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is structured in advanced installments to cover

This is the first international Chemistry, Manufacturing and Controls (CMC) development and manufacturing project empowered by the Oncolytic Virus contract development and manufacturing organization (CDMO) platform, which has

The new facility also facilitates the production of advanced and difficult-to-manufacture solid dosage forms such as tablets and capsules, in addition to the manufacturing of novel CAR-T cell